Comparison

MOTS-c vs SLU-PP-332:
identity, evidence and status

One is a peptide the body makes; the other is a laboratory compound that is not a peptide. The same questions asked of both: what each is, what has been studied and in what, and where each stands with regulators and in sport.

Short answerCompound research · 7 min read · Updated 21 Nov 2026

MOTS-c is a peptide of 16 amino acids encoded in mitochondrial DNA; SLU-PP-332 is not a peptide but a small synthetic molecule designed to activate the estrogen-related receptors. Studies that gave either used cells and animals, and we found no published study that gave either to people (21 November 2026). WADA’s 2027 List names both in class S4.4.1.

Key takeaways

  • MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA; SLU-PP-332 is a small synthetic molecule, C18H14N2O2, with no amino acids, so it is not a peptide.
  • Studies that gave either compound used cells and animals (rodents for MOTS-c, mice for SLU-PP-332); these are not evidence of an effect in people.
  • We found no published study that gave MOTS-c or SLU-PP-332 to people (21 Nov 2026); a placebo-controlled phase 2 trial of MOTS-c is recruiting, and ClinicalTrials.gov lists none for SLU-PP-332.
  • FDA staff reviewed MOTS-c in 2026 and found “a lack of evidence to evaluate the effectiveness” for the uses nominated to them; we found no FDA review of SLU-PP-332.
  • WADA has named MOTS-c in class S4.4.1 since the 2025 List; the 2027 List, in force from 1 January 2027, adds SLU-PP-332 to the same class, prohibited at all times.

01MOTS-c vs SLU-PP-332 in one table

The same questions for both, dated 21 November 2026.

QuestionMOTS-cSLU-PP-332
What it isA peptide of 16 amino acids, encoded in mitochondrial DNA inside the 12S rRNA gene; described in 2015Not a peptide. A small synthetic molecule, C18H14N2O2, designed as an agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ; reported in a 2023 paper
Made by the bodyYes; researchers have measured it in blood and muscleNo; it was designed and made in a laboratory
Studies that gave itRodents and cells (T3, T4)Mice and cells (T3, T4)
Human studiesNone published that gave it to people; studies in people measured the body’s own levels (T2). A registered phase 2 trial is recruiting, with no resultsNone found, published or registered. Laboratory work used human cells and human liver preparations
Regulator review of the evidenceFDA staff, 2026: “a lack of evidence to evaluate the effectiveness” for the uses nominated to themWe found none
United StatesDrugs@FDA lists no product. In FDA’s compounding Category 2 from 29 Sep 2023 to 22 Apr 2026; named in HHS’s October 2026 draft policy, which “is not binding”Drugs@FDA lists no product. Not named on FDA’s 503A nomination list (updated 14 May 2026), on its compounding safety-risk page or in the HHS policy
United KingdomNo results on the emc medicines database (21 Nov 2026)No results on the emc medicines database (21 Nov 2026)
AustraliaNot named in the Poisons Standard October 2026; we draw no scheduling conclusion of our ownNot named in the Poisons Standard October 2026; we draw no scheduling conclusion of our own
Sport (WADA)Named in class S4.4.1, metabolic modulators, since the 2025 List; prohibited at all timesNot named in the 2026 List. Named in class S4.4.1 of the 2027 List, in force 1 Jan 2027; prohibited at all times

If you searched “slu-pp-332 vs mots-c”, the first difference is the class of molecule: one is a peptide the body makes, the other is a laboratory compound that is not a peptide. Everything about MOTS-c on its own: the MOTS-c guide.

02How do MOTS-c and SLU-PP-332 differ as molecules?

Three differences that a lab, a regulator and a reader can check. Each card shows one.

MOTS-c

A peptide of 16 amino acids

A chain of amino acids encoded in mitochondrial DNA. PubChem lists it at 2,174.6 g/mol.

SLU-PP-332

Not a peptide

A small synthetic molecule with no amino acids. PubChem lists it at 290.3 g/mol, less than a seventh of MOTS-c’s mass (our calculation from PubChem).

Mechanism

Different proposed targets

Cell work proposed AMPK, a cell energy sensor, for MOTS-c; FDA staff say its molecular target “remains unknown”. SLU-PP-332 was designed to bind the ERR receptors.

How a lab tells them apart. By mass, as the cards show. A purity percentage alone cannot show which compound a vial holds; the identity result on that lot’s report can.

03What have studies of each measured, and in which models?

One row per study cited here. Rows name the model and what was measured, not what to expect. Animal and cell findings are not evidence of an effect in people.

CompoundStudyModel and nWhat was measuredTier
MOTS-cLee et al., 2015Cells and mice; the paper that described MOTS-cCell metabolism, the folate cycle and AMPK activity; insulin response in miceT4, T3
MOTS-cReynolds et al., 2021Mice aged 2, 12 and 22 months, 5 to 19 per group; a late-life cohort of 18 given MOTS-c and 19 control male miceTreadmill performance; grip strength, stride length and a 60-second walking testT3
MOTS-cReynolds et al., 202110 young men who cycled; nothing was given to themThe body’s own MOTS-c in muscle and blood before and after exerciseT2
SLU-PP-332Billon et al., 2023A mouse muscle cell line; male mice, 6 per group in the treadmill testCell respiration; running time and distance on a treadmill; grip strength; muscle fibre typesT4, T3
SLU-PP-332Wang et al., 2023Mice aged 21 months, given it for 8 weeksKidney measures, including mitochondrial function and signalling proteinsT3
SLU-PP-332Xu et al., 2024Mice with surgically induced pressure overload of the heart; heart cellsHeart function on ultrasound, gene activity, metabolite profilesT3, T4
SLU-PP-332Bonanni et al., 2025Muscle cells grown from biopsies of 10 womenProtein expression and cell measures in the dishT4

Who did the work. The two MOTS-c mouse studies come from the group that described it; in 2021, two of its members declared consulting roles and shares in CohBar, Inc. Most SLU-PP-332 papers come from the group that designed it; in 2023, three authors declared stock in Myonid Therapeutics, “which focuses on ERR based therapeutics”. Material sold online is not the product these studies tested. T2 is small or uncontrolled human research, T3 animal studies and T4 cell studies: how we grade evidence.

04Has either been given to people in a study?

Not in any published study we found (PubMed and ClinicalTrials.gov, 21 November 2026). One trial of MOTS-c is registered; none of SLU-PP-332 is.

  1. 2015MOTS-c described

    A University of Southern California group reports a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene, from cell and mouse work.

  2. 2021MOTS-c measured in people

    Its own levels are measured before and after exercise in 10 young men; nothing is given to them.

  3. 2023SLU-PP-332 reported

    Researchers in St. Louis report a synthetic ERR agonist and test it in cells and mice.

  4. Feb 2026A MOTS-c trial starts

    NCT07505745, a randomised, placebo-controlled phase 2 trial planned for 120 patients aged 18 to 65, no healthy volunteers. It asks whether an insulin-sensitivity index and adverse events differ from placebo.

  5. 2026Anti-doping labs map SLU-PP-332

    Laboratories in Cologne and Los Angeles describe its breakdown products, made with human liver preparations in the lab, for doping control. No person is given the compound.

  6. Nov 2026No results, no SLU-PP-332 trial

    The MOTS-c trial is recruiting with no results. ClinicalTrials.gov lists no record for SLU-PP-332, and none of its 11 PubMed records describes giving it to people.

For MOTS-c, FDA staff wrote in 2026 that they “did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans”. Everything else on MOTS-c in people: the MOTS-c guide.

05Where do MOTS-c and SLU-PP-332 stand with regulators and in sport?

Regulators have reviewed one of the two. Status, dated 21 November 2026.

  1. 29 Sep 2023MOTS-c enters FDA Category 2

    FDA’s list of compounding substances that may present significant safety risks. We found SLU-PP-332 on no FDA compounding list.

  2. 1 Jan 2025WADA names MOTS-c

    In class S4.4.1, metabolic modulators, among activators of AMPK.

  3. 22 Apr–Jul 2026MOTS-c leaves Category 2 and is reviewed

    HHS records that neither the placement nor the removal changed its status under section 503A, that FDA staff recommended against listing it, and that the July 2026 advisory committee voted in favour.

  4. 30 Oct 2026HHS draft policy

    It names MOTS-c among six peptides; the notice calls it a draft that “is not binding”.

  5. 1 Jan 2027WADA names SLU-PP-332

    The 2027 List adds “SLU-PP-332, SLU-PP-915 and related substances” to class S4.4.1, “as examples of metabolic modulators acting particularly on oxidative metabolism”, in the words of WADA’s explanatory note.

Safety statements, and for which compound. FDA’s compounding page says drugs containing MOTS-c “may pose significant risk for immunogenicity for certain routes of administration” and that FDA “has not identified any human exposure data” on them. We found no FDA statement on SLU-PP-332 either way, so the absence of one says nothing about its safety.

UK and Australia. Neither name returned a result on the emc database (21 November 2026), which is not the full UK register. Neither is named in Australia’s Poisons Standard October 2026; we draw no scheduling conclusion of our own. For peptides, the TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” Sport, in detail: is MOTS-c banned in sport?

06What we don’t know about MOTS-c and SLU-PP-332

Whether either does anything in people

We found no published study that gave MOTS-c or SLU-PP-332 to people (PubMed and ClinicalTrials.gov, 21 Nov 2026). The one registered MOTS-c trial has no results.

Whether mouse results carry over

Every study that gave either compound used cells or animals: rodents for MOTS-c, mice for SLU-PP-332. FDA staff call the clinical relevance of the MOTS-c animal findings “currently unknown”.

How the body handles either one

FDA staff identified no human exposure data for MOTS-c. For SLU-PP-332, the human data we found are breakdown products made in the lab from liver preparations.

Which compound a vial holds

The two differ more than sevenfold in mass (our calculation from PubChem). Only the identity result on that lot’s report shows which compound a sample is.

How to find the identity line on a lab report: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.

RefSources

  1. PubChem. MOTS-c, CID 146675088 (C101H152N28O22S2, 2174.6 g/mol); SLU-PP-332, CID 5404083 (C18H14N2O2, 290.3 g/mol). Compound records, read 21 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/5404083
  2. Lee C, Zeng J, Drew BG, et al. [Description of MOTS-c, with cell and mouse experiments on metabolism.] Cell Metab, 2015;21(3):443–454. PMID 25738459; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/25738459/
  3. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c in mice of different ages, and natural MOTS-c levels in exercising men.] Nat Commun, 2021;12(1):470. PMID 33473109; abstract and competing-interests statement read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/33473109/
  4. Billon C, Sitaula S, Banerjee S, et al. [Design of SLU-PP-332, with cell and mouse experiments.] ACS Chem Biol, 2023;18(4):756–771. PMID 36988910; full text PMC11584170 (methods, figure legends, competing interests) read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/36988910/
  5. Wang XX, Myakala K, Libby AE, et al. [SLU-PP-332 in 21-month-old mice: kidney measures.] Am J Pathol, 2023;193(12):1969–1987. PMID 37717940; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/37717940/
  6. Xu W, Billon C, Li H, et al. [Two ERR agonists, SLU-PP-332 and SLU-PP-915, in a mouse pressure-overload heart model and in heart cells.] Circulation, 2024;149(3):227–250. PMID 37961903; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/37961903/
  7. Bonanni R, Falvino A, Matticari A, et al. [SLU-PP-332 in muscle cells grown from biopsies of 10 women.] Front Physiol, 2025;16:1616693. PMID 40692696; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/40692696/
  8. Möller T, Krug O, Thevis M. In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915: novel pan-ERR agonists with doping potential. Rapid Commun Mass Spectrom, 2026;40(8):e70039. PMID 41588687; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/41588687/
  9. Avliyakulov NK, Sobolevsky T, Ahrens E. [Breakdown products of SLU-PP-332 made in vitro with human liver fractions, for doping control.] Drug Test Anal, 2026;18(3):439–450. PMID 41688415; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/41688415/
  10. PubMed and ClinicalTrials.gov searches: SLU-PP-332 (quoted, unquoted and as SLUPP332), 11 PubMed records, none describing its administration to people (the one record without an abstract read by title); ClinicalTrials.gov, 0 records. MOTS-c name set with clinical-trial publication types, 5 records, all measuring the body’s own levels; ClinicalTrials.gov intervention “MOTS-c”, 5 records, one giving MOTS-c (NCT07505745). Database searches, 21 Nov 2026. clinicaltrials.gov/study/NCT07505745
  11. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: MOTS-c-related bulk drug substances. Advisory committee briefing, 2026 (pp. 7, 25, 31, 33); downloaded and read 21 Nov 2026 (SHA-1 c6b5bc55…). www.fda.gov/media/193347/download
  12. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  13. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A, and Drugs@FDA through the openFDA API (data last updated 20 Nov 2026): neither names SLU-PP-332; Drugs@FDA has no MOTS-c product (control search, somatropin: 12 records). List updated 14 May 2026; database queries, 21 Nov 2026. www.fda.gov/media/94155/download
  14. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026; read 21 Nov 2026 on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  15. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 21 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  16. World Anti-Doping Agency. Prohibited List 2027 (in force 1 Jan 2027), class S4.4.1, read beside the 2026 List; and the 2027 summary of major modifications and explanatory notes (undated in its text). PDFs downloaded 21 Nov 2026 (SHA-1 8e84d248…, 08b06d5a…, 6f12d63b…) and searched. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  17. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327), and the TGA’s Peptide products topic page (last updated 23 Sep 2026; Internet Archive capture of 5 Nov 2026, the newest; tga.gov.au did not respond to our tools). Standard’s as-made text searched for MOTS, mitochondrial and SLU, 21 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  18. Electronic medicines compendium (emc). Searches for “MOTS-c” and “SLU-PP-332”: “No search results” for each (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=SLU-PP-332

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is SLU-PP-332 a peptide?

No. It is a small synthetic molecule, C18H14N2O2, with no amino acids. MOTS-c is a peptide of 16 amino acids.

What is the difference between MOTS-c and SLU-PP-332?

MOTS-c is a peptide encoded in mitochondrial DNA that the body makes; SLU-PP-332 is a laboratory compound designed to activate the estrogen-related receptors. They differ in class, mass and proposed target.

Has either been given to people in a study?

Not in any published study we found (PubMed and ClinicalTrials.gov, 21 Nov 2026). A placebo-controlled phase 2 trial of MOTS-c is recruiting with no results, and no trial of SLU-PP-332 is registered.

Are MOTS-c and SLU-PP-332 on WADA’s Prohibited List?

Both are named in class S4.4.1, metabolic modulators, and prohibited at all times: MOTS-c since the 2025 List, SLU-PP-332 from the 2027 List, in force 1 January 2027.

How can a lab tell MOTS-c and SLU-PP-332 apart?

By mass: PubChem lists MOTS-c at 2,174.6 g/mol and SLU-PP-332 at 290.3 g/mol. The identity result on a lot’s report shows which compound a sample is; a purity percentage alone cannot.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page